Mike has 20 years experience in science-driven businesses in Europe, US and Asia and is motivated by the organizational challenges at the interface of science and business. Most recently, Mike was the President, Scientific Operations and Chief Scientific Officer with Aptuit. During an acquisition-driven expansion, he consolidated and integrated API, preclinical, formulation, solid state chemistry and drug product manufacturing operations. The organization grew from three locations to eight and employed 800+ staff. Mike also led efforts to penetrate large accounts using Strategic Alliance Management teams, allocated R&D investment in service-oriented solutions and managed the Scientific Advisory Board. Mike was a member of the Aptuit-Laurus Board of Directors.
Before Aptuit, he was Group Vice President at MDS Pharma Services where he managed the company’s largest operations and commercial organizations. Ten clinical and chemistry operating units were located in N. America and Europe with clients in N. America, Europe and Asia. Prior to MDS, Mike was the Group Director, Business Development for Huntingdon Life Sciences, UK.
A Fellow of the Chartered Association of Certified Accountants since 1986 with a range of experience in international finance leadership from a successful venture capital backed enterprise to public companies in the UK and USA. Ian has worked for Xpedite Systems, Inc in the Data Communications industry as Chief Financial Officer, CableData International in the Enterprise Software sector as Finance Director in addition to senior finance roles in Financial Services with Next plc. Ian set-up his own consultancy business in 2004 which included an assignment as Interim Finance Director for Xceleron from May 2008 leading to him becoming Finance Director for the company in December 2009.
Trained as a biochemist at University College Cardiff, Mark obtained his PhD in comparative drug metabolism (in vitro/in vivo correlations) from the University of London in 1988. He then spent 12 years in the R&D Department at the Horseracing Forensic Laboratory, conducting in vivo metabolism studies on compounds potentially used for doping racehorses, and developing analytical methods to detect their use. In 1999, he joined the Drug Metabolism Department at Covance, Harrogate, where he was involved in running regulatory pre-clinical and clinical A(D)ME studies. Mark joined Xceleron in January 2007. Throughout his career, Mark’s research activities have focused on novel detection methodologies for drugs and their metabolites, including immunoaffinity chromatography; direct coupling of gas and liquid chromatography; the use of 13C:12C ratios to detect abuse of endogenous steroids. The move to Xceleron, and the use of accelerator mass spectrometry as an ultra-sensitive, enabling technique in biomedical research, was therefore a logical progression.
Since joining Xceleron in 2003, Jeremy has been instrumental in developing fit-for-purpose applications of 14C tracer/AMS in clinical investigations. Jeremy combines a keen understanding of client need across a range of pharmaceutical stakeholder groups with a broad knowledge of how 14C tracer / AMS can be used to design novel and cost-effective clinical studies. Most recently, Jeremy has led or participated in the development of the following clinical solutions:
Jeremy is a Chemistry and Management Science graduate of Imperial College, London University. Prior to joining Xceleron, Jeremy held product development roles in Europe and Asia for Charles River, Mars / Masterfoods and Exxon Chemical .
Microdosing studies: a consideration on analytical technology choice
"...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."
Find out how we can help you accelerate your drug-development program.